Early conversion to a sirolimus-based, calcineurin-inhibitor-free immunosuppression in the SMART trial: Observational results at 24 and 36 months after transplantation

Transplant International

Volumn 25, Issue 4, 2012, Pages 416-423

  Guba, Markus ^a   Pratschke, Johann ^b   Hugo, Christian ^c   Krämer, Bernhard K ^d   Pascher, Andreas ^e   Pressmar, Katharina ^f   Hakenberg, Oliver ^g   Fischereder, Michael ^a   Brockmann, Jens ^h   Andrassy, Joachim ^a   Banas, Bernhard ⁱ   Jauch, Karl Walter ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY OF INNSBRUCK   (Austria)

^c UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^d UNIVERSITY OF HEIDELBERG   (Germany)

^e CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^f UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^g UNIVERSITY OF ROSTOCK   (Germany)

^h UNIVERSITY OF ZURICH   (Switzerland)

ⁱ UNIVERSITY HOSPITAL REGENSBURG   (Germany)

Author keywords

calcineurin inhibitor free immunosuppression; kidney transplantation; mammalian target of rapamycin; sirolimus

Indexed keywords

CREATININE; CYCLOSPORIN A; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; STEROID;

ABDOMINAL PAIN; AGE; ANEMIA; ARTICLE; CONNECTIVE TISSUE DISEASE; CREATININE BLOOD LEVEL; CYTOMEGALOVIRUS INFECTION; DIABETES MELLITUS; DIARRHEA; DRUG EFFICACY; DRUG FEVER; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EDEMA; FEMALE; FOLLOW UP; GASTROINTESTINAL DISEASE; GLOMERULUS FILTRATION RATE; GRAFT SURVIVAL; HEART DISEASE; HEPATOBILIARY DISEASE; HUMAN; HYPERLIPIDEMIA; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY DISEASE; KIDNEY FUNCTION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LEUKOPENIA; LYMPHOCELE; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; MUSCLE HYPERTONIA; MUSCULOSKELETAL DISEASE; NEUROLOGIC DISEASE; NUTRITIONAL DISORDER; OBSERVATIONAL STUDY; ORGAN DONOR; PNEUMONIA; PREDICTIVE VALUE; PRIORITY JOURNAL; RESPIRATORY TRACT DISEASE; SKIN DISEASE; STEROID THERAPY; SUBCUTANEOUS FAT DISORDER; SURGICAL PATIENT; SURVIVAL TIME; THROMBOCYTOPENIA; URINARY TRACT INFECTION; VASCULAR DISEASE; WOUND HEALING IMPAIRMENT;

CALCINEURIN; CREATININE; CYCLOSPORINE; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; SIROLIMUS; TOR SERINE-THREONINE KINASES;

EID: 84858444345     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/j.1432-2277.2012.01432.x     Document Type: Article

References (14)

1. Ekberg H, Tedesco-Silva H, Demirbas A, et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 2007; 357: 2562.
2. Budde K, Becker T, Arns W, et al. Everolimus-based, calcineurin- inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial. Lancet 2011; 377: 837.
3. Guba M, Pratschke J, Hugo C, et al. Renal function, efficacy, and safety of sirolimus and mycophenolate mofetil after short-term calcineurin inhibitor-based quadruple therapy in de novo renal transplant patients: one-year analysis of a randomized multicenter trial. Transplantation 2010; 90: 175.
4. Lebranchu Y, Thierry A, Toupance O, et al. Efficacy on renal function of early conversion from cyclosporine to sirolimus 3 months after renal transplantation: concept study. Am J Transplant 2009; 9: 1115.
5. Schena FP, Pascoe MD, Alberu J, et al. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial. Transplantation 2009; 87: 233.
6. Glotz D, Charpentier B, Abramovicz D, et al. Thymoglobulin induction and sirolimus versus tacrolimus in kidney transplant recipients receiving mycophenolate mofetil and steroids. Transplantation 2010; 89: 1511.
7. Vitko S, Margreiter R, Weimar W, et al. Three-year efficacy and safety results from a study of everolimus versus mycophenolate mofetil in de novo renal transplant patients. Am J Transplant 2005; 5: 2521.
8. Demopoulos L, Polinsky M, Steele G, et al. Reduced risk of cytomegalovirus infection in solid organ transplant recipients treated with sirolimus: a pooled analysis of clinical trials. Transplant Proc 2008; 40: 1407.
9. Haririan A, Morawski K, West MS, et al. Sirolimus exposure during the early post-transplant period reduces the risk of CMV infection relative to tacrolimus in renal allograft recipients. Clin Transplant 2007; 21: 466.
10. Humar A, Lebranchu Y, Vincenti F, et al. The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients. Am J Transplant 2010; 10: 1228.
11. Vigano M, Dengler T, Mattei MF, et al. Lower incidence of cytomegalovirus infection with everolimus versus mycophenolate mofetil in de novo cardiac transplant recipients: a randomized, multicenter study. Transpl Infect Dis 2010; 12: 23.
12. Stallone G, Infante B, Schena A, et al. Rapamycin for treatment of chronic allograft nephropathy in renal transplant patients. J Am Soc Nephrol 2005; 16: 3755.
13. Diekmann F, Budde K, Oppenheimer F, Fritsche L, Neumayer HH, Campistol JM,. Predictors of success in conversion from calcineurin inhibitor to sirolimus in chronic allograft dysfunction. Am J Transplant 2004; 4: 1869.
14. Flechner SM, Kobashigawa J, Klintmalm G,. Calcineurin inhibitor-sparing regimens in solid organ transplantation: focus on improving renal function and nephrotoxicity. Clin Transplant 2008; 22: 1.